CA2331318A1 - Compositions comprenant des composes a base de 2-phenyl-indole et de formulations d'oestrogenes - Google Patents

Compositions comprenant des composes a base de 2-phenyl-indole et de formulations d'oestrogenes Download PDF

Info

Publication number
CA2331318A1
CA2331318A1 CA002331318A CA2331318A CA2331318A1 CA 2331318 A1 CA2331318 A1 CA 2331318A1 CA 002331318 A CA002331318 A CA 002331318A CA 2331318 A CA2331318 A CA 2331318A CA 2331318 A1 CA2331318 A1 CA 2331318A1
Authority
CA
Canada
Prior art keywords
phenyl
alkyl
estrogens
hydroxy
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002331318A
Other languages
English (en)
Inventor
Barry Samuel Komm
James Harrison Pickar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2331318A1 publication Critical patent/CA2331318A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne l'utilisation de composés 3-[4-(2-phényl-indol-1-ylméthyl)-phényl]acrylamide et de composés 2-phényl-1-[4-(amino-1-yl-alc-1-ynyl)benzyl]-1H-indol-5-ol, utiles en tant qu'agents oestrogènes; elle concerne également des compositions pharmaceutiques et des méthodes de traitement dans lesquelles on utilise ces composés, lesquels correspondent à la formule générale (I) ou (II).
CA002331318A 1998-05-15 1999-05-11 Compositions comprenant des composes a base de 2-phenyl-indole et de formulations d'oestrogenes Abandoned CA2331318A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7960498A 1998-05-15 1998-05-15
US7964498A 1998-05-15 1998-05-15
US09/079,644 1998-05-15
US09/079,604 1998-05-15
PCT/US1999/010215 WO1999059969A1 (fr) 1998-05-15 1999-05-11 Compositions comprenant des composes a base de 2-phenyl-indole et de formulations d'oestrogenes

Publications (1)

Publication Number Publication Date
CA2331318A1 true CA2331318A1 (fr) 1999-11-25

Family

ID=26762198

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002331318A Abandoned CA2331318A1 (fr) 1998-05-15 1999-05-11 Compositions comprenant des composes a base de 2-phenyl-indole et de formulations d'oestrogenes

Country Status (6)

Country Link
EP (1) EP1080073A1 (fr)
JP (1) JP2002515484A (fr)
CN (1) CN1309637A (fr)
AU (1) AU3894299A (fr)
CA (1) CA2331318A1 (fr)
WO (1) WO1999059969A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003989A2 (fr) * 2000-07-06 2002-01-17 Wyeth Therapie permettant d'inhiber l'incontinence du sphincter
JP2004502731A (ja) * 2000-07-06 2004-01-29 ワイス スタチン、エストロゲン剤および所望によるエストロゲンの組み合わせ
US6376486B1 (en) 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
US6455568B2 (en) 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
MXPA02012897A (es) * 2000-07-06 2003-10-24 Wyeth Corp Combinaciones de bisfosfonatos, agentes estrigenicos y opcionalmente estrogenos.
EP1990051A1 (fr) * 2000-07-06 2008-11-12 Wyeth Combinaisons d'inhibiteurs spécifiques de recaptage de la sérotonine et d'agents ostrogéniques
EP1656938A1 (fr) * 2000-07-06 2006-05-17 Wyeth Combinaisons d'inhibiteurs spécifiques du recaptage de la sérotonine avec des agents oestrogéniques
AU2001271784A1 (en) * 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
US20020173499A1 (en) * 2001-03-16 2002-11-21 Wyeth Estrogen replacement therapy
DE10117441A1 (de) * 2001-04-03 2002-10-10 Schering Ag 1-Indolylderivate, deren Verwendung zur Herstellung von Arzneimitteln, ein Verfahren zur Herstellung der 1-Indolylderivate sowie 1-Indolylderivate enthaltende pharmzeutische Präparate
ATE321754T1 (de) 2001-05-22 2006-04-15 Lilly Co Eli 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
ES2236536T3 (es) 2001-05-22 2005-07-16 Eli Lilly And Company Derivados tetrahidroquinolino para la inhibicion de enfermedades asociadas con la privacion de estrogenos o con una respuesta fisiologica aberrante a estrogenos endogenos.
EP1411922A1 (fr) 2001-07-31 2004-04-28 Pfizer Products Inc. Compositions pharmaceutiques, necessaires et methodes faisant intervenir des combinaisons d'agonistes/antagonistes des oestrogenes, d'oestrogenes et de progestines
PT1451167E (pt) 2001-12-10 2006-07-31 Ortho Mcneil Pharm Inc Fenilalcinos
US20040002604A1 (en) 2001-12-10 2004-01-01 Richard Apodaca Phenylalkynes
MXPA05005830A (es) * 2002-12-02 2006-02-08 Johnson & Johnson Metodos para preparar derivados de fenilalquino.
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CN104098499B (zh) * 2013-04-08 2016-05-04 上海医药工业研究院 5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1h-吲哚的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2077675T3 (es) * 1989-03-10 1995-12-01 Endorecherche Inc Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos.
CA2135160A1 (fr) * 1992-05-08 1993-11-25 Otsuka Pharmaceutical Factory, Inc. Derive de l'indole
DE4335876A1 (de) * 1993-10-17 1995-04-20 Schering Ag Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
DK0746544T3 (da) * 1994-02-22 1999-06-07 Merrell Pharma Inc Indolderivater til behandling af østrogenafhængige neoplasmer og sygdomme
DE4426625A1 (de) * 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US5552401A (en) * 1995-02-28 1996-09-03 Eli Lilly And Company 2-benzyl-3-arylbenzothiophenes
DE69707189T2 (de) * 1996-04-19 2002-06-20 American Home Products Corp., Madison Östrogene Verbindungen
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof

Also Published As

Publication number Publication date
CN1309637A (zh) 2001-08-22
AU3894299A (en) 1999-12-06
EP1080073A1 (fr) 2001-03-07
JP2002515484A (ja) 2002-05-28
WO1999059969A1 (fr) 1999-11-25

Similar Documents

Publication Publication Date Title
EP0802184B1 (fr) N-Benzyl-2-phénylindoles comme agents estrogènes
US5780497A (en) 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5880137A (en) 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US6583170B1 (en) 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
US8815934B2 (en) 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations
AU760378B2 (en) 2-phenyl-1-(4-(2-aminoethoxy)-benzyl)-indole in combination with estrogens
US5985910A (en) 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents
CA2331318A1 (fr) Compositions comprenant des composes a base de 2-phenyl-indole et de formulations d'oestrogenes
US6159959A (en) Combined estrogen and antiestrogen therapy
CA2203079C (fr) 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]indoles en tant qu'agents estrogeniques
MXPA00011170A (en) Compositions comprising 2-phenyl-indole compounds and estrogen formulations
EP1082319B1 (fr) Agents oestrogenes derives de benzocarbazole et d'indenoindole
HK1002862B (en) N-benzyl-2-phenylindoles as estrogenic agents
CA2203074A1 (fr) Substance a action estrogene
CA2203073A1 (fr) Substance a action estrogene
HK1031691B (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
MXPA00011178A (en) 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens
MXPA97002866A (en) Estrogeni agents

Legal Events

Date Code Title Description
FZDE Dead